Silo Pharma Inc. (NASDAQ: SILO) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering SPC-15, its lead intranasal therapeutic for post-traumatic stress disorder (PTSD). The patent, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior,” includes claims that protect both the composition of SPC-15 and methods of using it to prevent or delay stress-induced behavioral responses. This allowance indicates that the USPTO has completed its examination and determined that the application meets the requirements for patentability, meaning the patent will be granted shortly.
The significance of this development lies in the competitive advantage it provides Silo Pharma in the burgeoning field of mental health therapeutics. PTSD affects millions of people worldwide, and current treatment options often have limitations. SPC-15, with its intranasal delivery, could offer a more accessible and potentially faster-acting option. The U.S. patent protection is a critical component of Silo’s strategy as it advances SPC-15 through clinical development. It adds to the company’s growing biopharmaceutical intellectual property portfolio, which already includes a corresponding patent issued by the Japan Patent Office earlier this year. This international protection underscores the global potential of SPC-15 and positions Silo to pursue partnerships or licensing opportunities in key markets.
For investors, the Notice of Allowance reduces regulatory risk and enhances the value of Silo’s pipeline. It signals that the company’s innovative approach to stress-induced psychiatric disorders is recognized by a major patent authority. Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its portfolio includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. The company conducts research in collaboration with leading universities and laboratories.
The PTSD therapeutic market is highly competitive, with several companies vying for a share. However, SPC-15’s unique intranasal formulation and its potential to prevent stress-induced fear and anxiety could differentiate it from existing treatments. If successful in clinical trials, SPC-15 could address a significant unmet need, particularly for patients who do not respond adequately to current therapies. The patent allowance also provides a barrier to entry for potential competitors, allowing Silo to capitalize on its investment in research and development.
To view the full press release, visit https://ibn.fm/Hh4Z6. For more information about Silo Pharma, visit silopharma.com. The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO. BioMedWire is a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. For more information, visit https://www.BioMedWire.com.
